✨ Free AI Report
Celldex Therapeutics: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Celldex Therapeutics
Company Research

Celldex Therapeutics: Business Overview, Financials & Competitive Analysis

Celldex Therapeutics is emerging as an attractive biotech pick for 2026, driven by its advancing immunology pipeline and promising clinical data. Barzolvolimab is a humanized monoclonal antibody with a completely nove...

Analyst-debate audio for Celldex Therapeutics

AskCyborg analysts argue the bull and bear cases for Celldex Therapeutics across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
7/ 10Strong

Cyborg Score thesis

With pipeline progress, clinical milestones, and premium pricing potential creating multiple catalysts, CLDX presents an...

Read the full analyst-debate transcript →
Industry Biopharmaceutical - Immunotherapy and Monoclonal Antibodies
2 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 28, 2026
AI-Verified Research
30+ Page Report

Get the Latest Celldex Therapeutics Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Celldex Therapeutics Overview

Pro stress-test →

Celldex Therapeutics is emerging as an attractive biotech pick for 2026, driven by its advancing immunology pipeline and promising clinical data. Barzolvolimab is a humanized monoclonal antibody with a completely novel mechanism of action that uniquely targets the root cause of cold urticaria and symptomatic dermographism—the mast cell.

Strategic Profile

Pro stress-test →

Barzo is uniquely positioned as a "pipeline in a drug," targeting multiple mast cell diseases and commanding potential premium pricing. Management suggests that barzo's durable efficacy—extending beyond a year of dosing—could support substantially higher reimbursement, comparable to Dupixent's $60,000 annual cost.

Competitive Landscape

Pro stress-test →

Celldex is pioneering new horizons in immunology to deliver life-changing therapies, pursuing novel antibody-based treatments that engage the human immune system and directly affect critical pathways to improve lives of patients with allergic, inflammatory and autoimmune disorders. The mast cell-targeting immunology space includes competitors developing alternative approaches to urticaria and related conditions.

Industry Context

Celldex Therapeutics operates in Biopharmaceutical - Immunotherapy and Monoclonal Antibodies.

Key facts

Headquarters: Hampton, New Jersey, US · Revenue: $0.12M (Q4 2025) · Market cap: $2.02B

What the analysts stress-tested

The top findings that survived the multi-agent debate for Celldex Therapeutics.

  • Phase 2 open-label extension data shows complete response rates at Week 20 of 62% (ColdU) and 60% (SD), with repeat complete response reaching 82% (ColdU) and 86% (SD) among prior responders.
  • Topline Phase 3 data expected Q4 2026 with BLA submission planned for 2027.
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • Mar 2026Presented positive Phase 2 open-label extension data on barzolvolimab retreatment in Cold urticaria and symptomatic dermographism at AAAAI 2026.
  • Feb 2026Completion of enrollment in two large EMBARQ-CSU Phase 3 trials with 1,939 patients coincided with a 24.07% stock gain.
  • +1 moreTrack every material event for Celldex Therapeutics as it happens. Explore monitoring →
Get alerted when Celldex Therapeutics has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

DupixentCurrently used for similar allergic/inflammatory indications with ~$60,000 annual pricing→Other AntihistaminesExisting first-line treatments for urticaria that barzolvolimab may improve upon→

Compare Celldex Therapeutics with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Celldex Therapeutics operates in Biopharmaceutical - Immunotherapy and Monoclonal Antibodies. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceutical - Immunotherapy and Monoclonal Antibodies research →
NEW · MCP server

Ask your AI assistant about Celldex Therapeutics

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Celldex Therapeutics and its top competitor on Cyborg Score”
“What did Celldex Therapeutics do this quarter?”
“Is Celldex Therapeutics a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Celldex Therapeutics do?+
Celldex Therapeutics is emerging as an attractive biotech pick for 2026, driven by its advancing immunology pipeline and promising clinical data. Barzolvolimab is a humanized monoclonal antibody with a completely nove...
What is Celldex Therapeutics's Cyborg Score?+
Celldex Therapeutics has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Celldex Therapeutics's main competitors?+
Named competitors include Dupixent, Other Antihistamines. The full competitive landscape is in the AskCyborg report.
How can I get the full Celldex Therapeutics research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Celldex Therapeutics research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Celldex Therapeutics over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.